Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001104659-23-033350
Filing Date
2023-03-16
Accepted
2023-03-16 16:36:53
Documents
14
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K/A tm239725d1_10ka.htm   iXBRL 10-K/A 105900
2 EXHIBIT 31.1 tm239725d1_ex31-1.htm EX-31.1 3152
3 EXHIBIT 31.2 tm239725d1_ex31-2.htm EX-31.2 3208
  Complete submission text file 0001104659-23-033350.txt   331323

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA clrb-20221231.xsd EX-101.SCH 3030
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE clrb-20221231_lab.xml EX-101.LAB 36509
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clrb-20221231_pre.xml EX-101.PRE 23996
8 EXTRACTED XBRL INSTANCE DOCUMENT tm239725d1_10ka_htm.xml XML 5548
Mailing Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE FLORHAM PARK NJ 07932 (608) 441-8120
Cellectar Biosciences, Inc. (Filer) CIK: 0001279704 (see all company filings)

EIN.: 043321804 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-36598 | Film No.: 23739362
SIC: 2834 Pharmaceutical Preparations